Caribou Biosciences
CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.
Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.
Pages like this
not linked directly; found by shared links- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyAllogene Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares Allogeneic donor and iPSC master cell banks, Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines.
- CompanyFate Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- InstitutionChinese PLA General Hospital
Shares CRISPR functional genomics, CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- CompanySana Biotechnology
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.